Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care”
Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline TumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological … Continue reading “Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries”
POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition Results garnered from company’s HSC optimization are unparalleled in field Soluble Biotech lands first major contract, signifying major company milestone Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and … Continue reading “Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits”
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview”
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for … Continue reading “NetworkNewsAudio – Predictive Oncology Inc. (NASDAQ: POAI) Interview”
Recent study reports CAGR of 9.7% in precision medicine space. Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies. One of POAI’s primary projects is building multi-omic predictive models of tumor drug response A recent study of the global precision medicine market indicates a bright future for the industry, especially … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Industry Leader in Growing Precision Medicine Market”
Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://nnw.fm/38wOl). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. Under the contract, Soluble Biotech will provide … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books”
Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline Company also revealed its … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (http://nnw.fm/XeQG6). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!”
